Phase 3 N=33 Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients
Hypertension Secondary to Kidney Transplant
Primary: Number of Participants Who Are Non Dippers — 7; 12 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,019 Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection
Wound Infection · Abscess · Systemic Inflammation
Primary: Early Clinical Response — 403; 416; 100; 86 participants
Phase 3 N=323 Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan
Anemia; Hemodialysis Dependent Chronic Kidney Disease
Primary: Mean Hb Level of Week 20 and Week 24 — 10.61; 10.65 g/dL
Phase 3 N=38 A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia
Schizophrenia
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 11; 15; 11 Participants
Phase 3 N=248 Long-Term Study of MP-214 in Patients With Schizophrenia
Schizophrenia
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 67; 92; 50 Participants
Phase 3 N=53 A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia
Insomnia
Primary: Percentage of Overall Participants Who Transitioned to LEM at the End of the Titration Period of Core Study — 81.1 percentage of participants
Phase 3 N=2,340 Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)
Pneumococcal Infections · Pneumonia, Pneumococcal
Primary: Percentage of Participants With a Solicited Injection-site Adverse Event Following Vaccination With Separate V114 Lots — 10.2; 11.5; 11.0; 66.1 Percentage of participants
Phase 3 N=508 Safety and Efficacy of MP-214 in Patients With Schizophrenia
Schizophrenia
Primary: Change in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 — -10.4; -13.8; -14.0; -20.2 units on a scale
Phase 3 N=304 Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan
Anemia; Non-dialysis Dependent Chronic Kidney Disease
Primary: Mean Hb Level of Week 20 and Week 24 — 11.66; 11.93 g/dL
Phase 3 N=28 Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder
Cannabis Use Disorder · Attention-deficit/Hyperactivity Disorder
Primary: Marijuana Abstinence — 0; 2 Participants
Phase 3 N=493 Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Acute Otitis Externa
Acute Otitis Externa
Primary: Therapeutic Cure (Clinical + Microbiological Cure) — 63; 49; 20 Participants
Phase 3 N=10 Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome
Short Bowel Syndrome
Primary: Number of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Weight-normalized Parenteral Support (PS) Volume at End of Treatment/Early…
Phase 3 N=17 Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043)
Hypogonadotropic Hypogonadism
Primary: Change From Baseline in Log-Transformed Testicular Volume (TV) to Week 64 — 1.5; 14.5 mL
Phase 3 N=336 Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Macular Degeneration
Primary: Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) Letter Score for the Study Eye — -0.3; -0.5 Letters read correctly…
Phase 3 N=258 To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma
Follicular Lymphoma
Primary: Primary Efficacy Endpoint - Overall Response Rate by 7 Months — 108; 104 Participants